CAM
TRML

Cresset Asset Management’s Tourmaline Bio TRML Stock Holding History

Cresset Asset Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,944
Closed -$204K – 2193
2024
Q3 		$204K Buy
+7,944
New +$133K ﹤0.01% 1977

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Cresset Asset Management's TRML Position: Q4 2024 in Review

Cresset Asset Management sold out of Tourmaline Bio (TRML) in Q4 2024, closing a stake of 7,944 shares — an estimated $204K sold.

Cresset Asset Management first reported a position in TRML in Q3 2024 and held it in 1 quarter. The position peaked at $204K in Q3 2024. 101 funds tracked by Wall St. Rank hold TRML as of Q4 2024.

  • Cresset Asset Management reported no remaining Tourmaline Bio position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 7,944 Tourmaline Bio shares in Q4 2024, an estimated $204K.
  • Cresset Asset Management first reported a position in Tourmaline Bio in Q3 2024 and held it in 1 quarter.
  • Cresset Asset Management's Tourmaline Bio position peaked at $204K in Q3 2024.
  • 101 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.